1
|
Scheffler M, Holzem A, Kron A, Nogova L, Ihle MA, von Levetzow C, Fassunke J, Wömpner C, Bitter E, Koleczko S, Abdulla DSY, Michels S, Fischer R, Riedel R, Weber JP, Westphal T, Gerigk U, Kern J, Kaminsky B, Randerath W, Kambartel KO, Merkelbach-Bruse S, Büttner R, Wolf J. Co-occurrence of targetable mutations in Non-small cell lung cancer (NSCLC) patients harboring MAP2K1 mutations. Lung Cancer 2020; 144:40-48. [PMID: 32361034 DOI: 10.1016/j.lungcan.2020.04.020] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/21/2020] [Revised: 04/16/2020] [Accepted: 04/18/2020] [Indexed: 02/04/2023]
Abstract
BACKGROUND MAP2K1 mutations are rare in non-small cell lung cancer (NSCLC) and considered to be mutually exclusive from known driver mutations. Activation of the MEK1-cascade is considered pivotal in resistance to targeted therapy approaches, and MAP2K1 K57 N mutation could be linked to resistance in preclinical models. We set out this study to detect MAP2K1 mutations and potentially targetable co-mutations using a molecular multiplex approach. METHODS Between 2012 and 2018, we routinely analyzed 14.512 NSCLC patients with two next-generation sequencing (NGS) panels. In a subset of patients, fluorescence in-situ hybridization was performed to detect rearrangements or amplifications. We assessed clinical parameters and co-occurring mutations and compared treatment outcomes of different forms of systemic therapy. RESULTS We identified 66 (0.5%) patients with MAP2K1 mutations. Both adenocarcinoma (n = 62) and squamous cell carcinoma (n = 4) histology. The presence of the mutations was linked to smoking, and transversions were more common than transitions. K57 N was the most frequent MAP2K1 mutation (n = 25). Additional mutations were found in 57 patients (86.4%). Mutations of TP53 were detected in 33 patients, followed by KEAP1 mutations in 28.1%. 24 patients (36.4%) had either MAP2K1-only or a co-occurring aberration considered targetable, including EGFR mutations, a BRAF V600E mutation and ROS1 rearrangements. Outcome analyses revealed a trend toward benefit from pemetrexed treatment. CONCLUSION Our analysis shows that MAP2K1-mutated NSCLC patients might frequently present with potentially targetable aberrations. Their role in providing resistance in these subtypes and the possible therapeutic opportunities justify further analyses of this rare NSCLC subgroup.
Collapse
Affiliation(s)
- Matthias Scheffler
- University Hospital of Cologne, Lung Cancer Group Cologne, Department I of Internal Medicine, Cologne, Germany
| | - Alessandra Holzem
- University Hospital of Cologne, Lung Cancer Group Cologne, Department I of Internal Medicine, Cologne, Germany
| | - Anna Kron
- University Hospital of Cologne, Lung Cancer Group Cologne, Department I of Internal Medicine, Cologne, Germany
| | - Lucia Nogova
- University Hospital of Cologne, Lung Cancer Group Cologne, Department I of Internal Medicine, Cologne, Germany
| | - Michaela A Ihle
- University of Cologne, Cologne Institute of Pathology, Cologne, Germany
| | - Cornelia von Levetzow
- University Hospital of Cologne, Lung Cancer Group Cologne, Department I of Internal Medicine, Cologne, Germany
| | - Jana Fassunke
- University of Cologne, Cologne Institute of Pathology, Cologne, Germany
| | - Claudia Wömpner
- University Hospital of Cologne, Lung Cancer Group Cologne, Department I of Internal Medicine, Cologne, Germany
| | - Elisabeth Bitter
- University Hospital of Cologne, Lung Cancer Group Cologne, Department I of Internal Medicine, Cologne, Germany
| | - Sophia Koleczko
- University Hospital of Cologne, Lung Cancer Group Cologne, Department I of Internal Medicine, Cologne, Germany
| | - Diana S Y Abdulla
- University Hospital of Cologne, Lung Cancer Group Cologne, Department I of Internal Medicine, Cologne, Germany
| | - Sebastian Michels
- University Hospital of Cologne, Lung Cancer Group Cologne, Department I of Internal Medicine, Cologne, Germany
| | - Rieke Fischer
- University Hospital of Cologne, Lung Cancer Group Cologne, Department I of Internal Medicine, Cologne, Germany
| | - Richard Riedel
- University Hospital of Cologne, Lung Cancer Group Cologne, Department I of Internal Medicine, Cologne, Germany
| | - Jan-Philipp Weber
- University Hospital of Cologne, Lung Cancer Group Cologne, Department I of Internal Medicine, Cologne, Germany
| | - Theresa Westphal
- University Hospital of Cologne, Lung Cancer Group Cologne, Department I of Internal Medicine, Cologne, Germany
| | - Ulrich Gerigk
- GFO Clinics Bonn, Marien-Hospital Bonn, Bonn, Germany
| | - Jens Kern
- KWM Missio Clinic, Würzburg, Germany
| | - Britta Kaminsky
- Bethanien Hospital Solingen, Clinic for Pulmonology and Allergology, Solingen, Germany
| | - Winfried Randerath
- Bethanien Hospital Solingen, Clinic for Pulmonology and Allergology, Solingen, Germany
| | | | | | - Reinhard Büttner
- University of Cologne, Cologne Institute of Pathology, Cologne, Germany
| | - Jürgen Wolf
- University Hospital of Cologne, Lung Cancer Group Cologne, Department I of Internal Medicine, Cologne, Germany.
| |
Collapse
|
2
|
Scheffler M, Ihle MA, Hein R, Merkelbach-Bruse S, Scheel AH, Siemanowski J, Brägelmann J, Kron A, Abedpour N, Ueckeroth F, Schüller M, Koleczko S, Michels S, Fassunke J, Pasternack H, Heydt C, Serke M, Fischer R, Schulte W, Gerigk U, Nogova L, Ko YD, Abdulla DSY, Riedel R, Kambartel KO, Lorenz J, Sauerland I, Randerath W, Kaminsky B, Hagmeyer L, Grohé C, Eisert A, Frank R, Gogl L, Schaepers C, Holzem A, Hellmich M, Thomas RK, Peifer M, Sos ML, Büttner R, Wolf J. K-ras Mutation Subtypes in NSCLC and Associated Co-occuring Mutations in Other Oncogenic Pathways. J Thorac Oncol 2018; 14:606-616. [PMID: 30605727 DOI: 10.1016/j.jtho.2018.12.013] [Citation(s) in RCA: 153] [Impact Index Per Article: 25.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/12/2018] [Revised: 10/31/2018] [Accepted: 12/10/2018] [Indexed: 12/23/2022]
Abstract
INTRODUCTION Although KRAS mutations in NSCLC have been considered mutually exclusive driver mutations for a long time, there is now growing evidence that KRAS-mutated NSCLC represents a genetically heterogeneous subgroup. We sought to determine genetic heterogeneity with respect to cancer-related co-mutations and their correlation with different KRAS mutation subtypes. METHODS Diagnostic samples from 4507 patients with NSCLC were analyzed by next-generation sequencing by using a panel of 14 genes and, in a subset of patients, fluorescence in situ hybridization. Next-generation sequencing with an extended panel of 14 additional genes was performed in 101 patients. Molecular data were correlated with clinical data. Whole-exome sequencing was performed in two patients. RESULTS We identified 1078 patients with KRAS mutations, of whom 53.5% had at least one additional mutation. Different KRAS mutation subtypes showed different patterns of co-occurring mutations. Besides mutations in tumor protein p53 gene (TP53) (39.4%), serine/threonine kinase 11 gene (STK11) (19.8%), kelch like ECH associated protein 1 gene (KEAP1) (12.9%), and ATM serine/threonine kinase gene (ATM) (11.9%), as well as MNNG HOS Transforming gene (MET) amplifications (15.4%) and erb-b2 receptor tyrosine kinase 2 gene (ERBB2) amplifications (13.8%, exclusively in G12C), we found rare co-occurrence of targetable mutations in EGFR (1.2%) and BRAF (1.2%). Whole-exome sequencing of two patients with co-occurring phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha gene (PIK3CA) mutation revealed clonality of mutated KRAS in one patient and subclonality in the second, suggesting different evolutionary backgrounds. CONCLUSION KRAS-mutated NSCLC represents a genetically heterogeneous subgroup with a high frequency of co-occurring mutations in cancer-associated pathways, partly associated with distinct KRAS mutation subtypes. This diversity might have implications for understanding the variability of treatment outcome in KRAS-mutated NSCLC and for future trial design.
Collapse
Affiliation(s)
- Matthias Scheffler
- University Hospital of Cologne, Lung Cancer Group Cologne, Department I of Internal Medicine, Cologne, Germany
| | - Michaela A Ihle
- University of Cologne, Cologne Institute of Pathology, Cologne, Germany
| | - Rebecca Hein
- University of Cologne, Institute of Medical Statistics, Informatics and Epidemiology, Cologne, Germany
| | | | - Andreas H Scheel
- University of Cologne, Cologne Institute of Pathology, Cologne, Germany
| | - Janna Siemanowski
- University of Cologne, Cologne Institute of Pathology, Cologne, Germany
| | - Johannes Brägelmann
- University of Cologne, Department for Translational Genomics, Cologne, Germany
| | - Anna Kron
- University Hospital of Cologne, Lung Cancer Group Cologne, Department I of Internal Medicine, Cologne, Germany
| | - Nima Abedpour
- University of Cologne, Department for Translational Genomics, Cologne, Germany
| | - Frank Ueckeroth
- University of Cologne, Cologne Institute of Pathology, Cologne, Germany
| | - Merle Schüller
- University Hospital of Cologne, Lung Cancer Group Cologne, Department I of Internal Medicine, Cologne, Germany
| | - Sophia Koleczko
- University Hospital of Cologne, Lung Cancer Group Cologne, Department I of Internal Medicine, Cologne, Germany
| | - Sebastian Michels
- University Hospital of Cologne, Lung Cancer Group Cologne, Department I of Internal Medicine, Cologne, Germany
| | - Jana Fassunke
- University of Cologne, Cologne Institute of Pathology, Cologne, Germany
| | - Helen Pasternack
- Pathology of the University Medical Center Schleswig-Holstein, Campus Luebeck and Research Center Borstel, Leibniz Center for Medicine and Biosciences
| | - Carina Heydt
- University of Cologne, Cologne Institute of Pathology, Cologne, Germany
| | - Monika Serke
- Lung Clinic Hemer, Department for Pulmonology and Thoracic Oncology, Hemer, Germany
| | - Rieke Fischer
- University Hospital of Cologne, Lung Cancer Group Cologne, Department I of Internal Medicine, Cologne, Germany
| | | | - Ulrich Gerigk
- GFO Clinics Bonn, Marien-Hospital Bonn, Bonn, Germany
| | - Lucia Nogova
- University Hospital of Cologne, Lung Cancer Group Cologne, Department I of Internal Medicine, Cologne, Germany
| | - Yon-Dschun Ko
- Evangelical Clinics of Bonn, Johanniter Hospital, Bonn, Germany
| | - Diana S Y Abdulla
- University Hospital of Cologne, Lung Cancer Group Cologne, Department I of Internal Medicine, Cologne, Germany
| | - Richard Riedel
- University Hospital of Cologne, Lung Cancer Group Cologne, Department I of Internal Medicine, Cologne, Germany
| | | | - Joachim Lorenz
- Hospital Lüdenscheid, Clinic for Pneumology, Internistic Intensive Medicine, Infectiology and Sleep Medicine, Lüdenscheid, Germany
| | - Imke Sauerland
- Hospital Lüdenscheid, Clinic for Pneumology, Internistic Intensive Medicine, Infectiology and Sleep Medicine, Lüdenscheid, Germany
| | - Winfried Randerath
- Bethanien Hospital Solingen, Clinic for Pulmonology and Allergology, Solingen, Germany
| | - Britta Kaminsky
- Bethanien Hospital Solingen, Clinic for Pulmonology and Allergology, Solingen, Germany
| | - Lars Hagmeyer
- Bethanien Hospital Solingen, Clinic for Pulmonology and Allergology, Solingen, Germany
| | - Christian Grohé
- Evangelic Lung Clinic Berlin, Department of Respiratory Diseases, Berlin, Germany
| | - Anna Eisert
- University Hospital of Cologne, Lung Cancer Group Cologne, Department I of Internal Medicine, Cologne, Germany
| | - Rieke Frank
- University Hospital of Cologne, Lung Cancer Group Cologne, Department I of Internal Medicine, Cologne, Germany
| | - Leonie Gogl
- University Hospital of Cologne, Lung Cancer Group Cologne, Department I of Internal Medicine, Cologne, Germany
| | - Carsten Schaepers
- University Hospital of Cologne, Lung Cancer Group Cologne, Department I of Internal Medicine, Cologne, Germany
| | - Alessandra Holzem
- University Hospital of Cologne, Lung Cancer Group Cologne, Department I of Internal Medicine, Cologne, Germany
| | - Martin Hellmich
- University of Cologne, Institute of Medical Statistics, Informatics and Epidemiology, Cologne, Germany
| | - Roman K Thomas
- University of Cologne, Department for Translational Genomics, Cologne, Germany
| | - Martin Peifer
- University of Cologne, Department for Translational Genomics, Cologne, Germany
| | - Martin L Sos
- University of Cologne, Department for Translational Genomics, Cologne, Germany
| | - Reinhard Büttner
- University of Cologne, Cologne Institute of Pathology, Cologne, Germany
| | - Jürgen Wolf
- University Hospital of Cologne, Lung Cancer Group Cologne, Department I of Internal Medicine, Cologne, Germany.
| |
Collapse
|
3
|
Frank R, Scheffler M, Merkelbach-Bruse S, Ihle MA, Kron A, Rauer M, Ueckeroth F, König K, Michels S, Fischer R, Eisert A, Fassunke J, Heydt C, Serke M, Ko YD, Gerigk U, Geist T, Kaminsky B, Heukamp LC, Clement-Ziza M, Büttner R, Wolf J. Clinical and Pathological Characteristics of KEAP1- and NFE2L2-Mutated Non-Small Cell Lung Carcinoma (NSCLC). Clin Cancer Res 2018; 24:3087-3096. [PMID: 29615460 DOI: 10.1158/1078-0432.ccr-17-3416] [Citation(s) in RCA: 103] [Impact Index Per Article: 17.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/15/2017] [Revised: 02/22/2018] [Accepted: 03/27/2018] [Indexed: 11/16/2022]
Abstract
Purpose:KEAP1 and NFE2L2 mutations are associated with impaired prognosis in a variety of cancers and with squamous cell carcinoma formation in non-small cell lung cancer (NSCLC). However, little is known about frequency, histology dependence, molecular and clinical presentation as well as response to systemic treatment in NSCLC.Experimental Design: Tumor tissue of 1,391 patients with NSCLC was analyzed using next-generation sequencing (NGS). Clinical and pathologic characteristics, survival, and treatment outcome of patients with KEAP1 or NFE2L2 mutations were assessed.Results:KEAP1 mutations occurred with a frequency of 11.3% (n = 157) and NFE2L2 mutations with a frequency of 3.5% (n = 49) in NSCLC patients. In the vast majority of patients, both mutations did not occur simultaneously. KEAP1 mutations were found mainly in adenocarcinoma (AD; 72%), while NFE2L2 mutations were more common in squamous cell carcinoma (LSCC; 59%). KEAP1 mutations were spread over the whole protein, whereas NFE2L2 mutations were clustered in specific hotspot regions. In over 80% of the patients both mutations co-occurred with other cancer-related mutations, among them also targetable aberrations like activating EGFR mutations or MET amplification. Both patient groups showed different patterns of metastases, stage distribution and performance state. No patient with KEAP1 mutation had a response on systemic treatment in first-, second-, or third-line setting. Of NFE2L2-mutated patients, none responded to second- or third-line therapy.Conclusions:KEAP1- and NFE2L2-mutated NSCLC patients represent a highly heterogeneous patient cohort. Both are associated with different histologies and usually are found together with other cancer-related, partly targetable, genetic aberrations. In addition, both markers seem to be predictive for chemotherapy resistance. Clin Cancer Res; 24(13); 3087-96. ©2018 AACR.
Collapse
Affiliation(s)
- Rieke Frank
- Lung Cancer Group Cologne, Department I of Internal Medicine, University Hospital of Cologne, Cologne, Germany.,Network Genomic Medicine (Lung Cancer), Cologne, Germany
| | - Matthias Scheffler
- Lung Cancer Group Cologne, Department I of Internal Medicine, University Hospital of Cologne, Cologne, Germany.,Network Genomic Medicine (Lung Cancer), Cologne, Germany
| | - Sabine Merkelbach-Bruse
- Network Genomic Medicine (Lung Cancer), Cologne, Germany.,Institute of Pathology, University Hospital of Cologne, Cologne, Germany
| | - Michaela A Ihle
- Network Genomic Medicine (Lung Cancer), Cologne, Germany.,Institute of Pathology, University Hospital of Cologne, Cologne, Germany
| | - Anna Kron
- Lung Cancer Group Cologne, Department I of Internal Medicine, University Hospital of Cologne, Cologne, Germany.,Institute of Pathology, University Hospital of Cologne, Cologne, Germany
| | - Michael Rauer
- Center for Molecular Medicine Cologne (CMMC), University of Cologne, Cologne, Germany.,Cologne Excellence Cluster for Cellular Stress Responses in Aging-Associated Diseases (CECAD) Research Center and Systems Biology of Ageing Cologne, University of Cologne, Cologne, Germany
| | - Frank Ueckeroth
- Network Genomic Medicine (Lung Cancer), Cologne, Germany.,Institute of Pathology, University Hospital of Cologne, Cologne, Germany
| | - Katharina König
- Network Genomic Medicine (Lung Cancer), Cologne, Germany.,Institute of Pathology, University Hospital of Cologne, Cologne, Germany
| | - Sebastian Michels
- Lung Cancer Group Cologne, Department I of Internal Medicine, University Hospital of Cologne, Cologne, Germany.,Network Genomic Medicine (Lung Cancer), Cologne, Germany
| | - Rieke Fischer
- Lung Cancer Group Cologne, Department I of Internal Medicine, University Hospital of Cologne, Cologne, Germany.,Network Genomic Medicine (Lung Cancer), Cologne, Germany
| | - Anna Eisert
- Lung Cancer Group Cologne, Department I of Internal Medicine, University Hospital of Cologne, Cologne, Germany.,Network Genomic Medicine (Lung Cancer), Cologne, Germany
| | - Jana Fassunke
- Network Genomic Medicine (Lung Cancer), Cologne, Germany.,Institute of Pathology, University Hospital of Cologne, Cologne, Germany
| | - Carina Heydt
- Network Genomic Medicine (Lung Cancer), Cologne, Germany.,Institute of Pathology, University Hospital of Cologne, Cologne, Germany
| | - Monika Serke
- Network Genomic Medicine (Lung Cancer), Cologne, Germany.,Department for Pulmonology and Thoracic Oncology, Lung Clinic Hemer, Hemer, Germany
| | - Yon-Dschun Ko
- Network Genomic Medicine (Lung Cancer), Cologne, Germany.,Johanniter Hospital, Evangelical Clinics of Bonn, Bonn, Germany
| | - Ulrich Gerigk
- Network Genomic Medicine (Lung Cancer), Cologne, Germany.,Marien-Hospital Bonn, GFO Clinics Bonn, Bonn, Germany
| | - Thomas Geist
- Network Genomic Medicine (Lung Cancer), Cologne, Germany.,Center Practice for Lung and Bronchial Diseases, Düsseldorf, Germany
| | - Britta Kaminsky
- Network Genomic Medicine (Lung Cancer), Cologne, Germany.,Clinic for Pulmonology and Allergology, Bethanien Hospital Solingen, Solingen, Germany
| | - Lukas C Heukamp
- Network Genomic Medicine (Lung Cancer), Cologne, Germany.,Institute of Pathology, University Hospital of Cologne, Cologne, Germany
| | - Mathieu Clement-Ziza
- Center for Molecular Medicine Cologne (CMMC), University of Cologne, Cologne, Germany.,Cologne Excellence Cluster for Cellular Stress Responses in Aging-Associated Diseases (CECAD) Research Center and Systems Biology of Ageing Cologne, University of Cologne, Cologne, Germany
| | - Reinhard Büttner
- Network Genomic Medicine (Lung Cancer), Cologne, Germany.,Institute of Pathology, University Hospital of Cologne, Cologne, Germany
| | - Jürgen Wolf
- Lung Cancer Group Cologne, Department I of Internal Medicine, University Hospital of Cologne, Cologne, Germany. .,Network Genomic Medicine (Lung Cancer), Cologne, Germany
| |
Collapse
|
4
|
Holzem A, Nogova L, Ihle MA, Wompner C, Bitter E, Michels SYF, Fischer RN, Kron A, Gerigk U, Kern J, Kaminsky B, Randerath W, Lorenz J, Kambartel KO, Merkelbach-Bruse S, Büttner R, Scheffler M, Wolf J. Co-occurrence of targetable aberrations in non-small cell lung cancer patients harboring MAP2K1 mutations. J Clin Oncol 2017. [DOI: 10.1200/jco.2017.35.15_suppl.e20059] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e20059 Background: MAP2K1 mutations are rare in non-small cell lung cancer (NSCLC) and considered to be mutually exclusive with known driver mutations. Activation of the MEK1-cascade might play a pivotal role in resistance to targeted inhibition of BRAF V600E, EML4-ALK and EGFR T790M. So far, however, only MAP2K1 K57N could be identified and linked functionally to resistance in preclinical models. Clinical trials combining specific inhibitors for predefined NSCLC subgroups with MEK inhibitors are ongoing. We sought to characterize frequency and type of MAP2K1-mutated NSCLC regarding curated targetable aberrations. Methods: Tumor tissue collected consecutively from 4590 NSCLC patients within the German Network Genomic Medicine (NGM) between 07/2014 and 07/2015 was analyzed for MAP2K1 mutations using next-generation sequencing (NGS) with a set of 102 amplicons in 14 genes. Clinical and molecular characteristics of these patients were determined and compared with an internal control group of NSCLC patients and an independent control group of The Cancer Genome Atlas (TCGA). Results: We identified 21 (0.5%) patients with MAP2K1 mutations. They were frequently found in adenocarcinomas (n = 20) and were significantly associated with smoking. The most common MAP2K1 mutation was K57N. Most of the patients (n = 16) had additional oncogenic driver aberrations, including mutations in ALK, EGFR or BRAF, ROS1 rearrangements and MET amplification. TP53 mutations were found in 11 patients. In only five patients (23.8%) MAP2K1 occurred exclusively. TCGA analysis revealed additional 10 patients with MAP2K1 mutations, whereof 9 had additional TP53 mutations and one had BRAF mutation. Whereof most patients in our cohort had stage IV NSCLC, all patients in TCGA were systemic treatment naive. Compared with local stages in TCGA, our findings strongly suggest that targetable co-occurring mutations might occur more frequently in advanced stage NSCLC patients. Conclusions: MAP2K1 mutations co-occur frequently with targetable aberrations in smoking stage IV patients. Combination of targeted therapy against known driver aberrations with MEK inhibitors might be a promising therapeutic approach for such patients.
Collapse
Affiliation(s)
| | - Lucia Nogova
- Lung Cancer Group Cologne, Center for Integrated Oncology, University Hospital Cologne, Cologne, Germany
| | - Michaela A. Ihle
- Institute of Pathology, University Hospital of Cologne, Cologne, Germany
| | - Claudia Wompner
- Lung Cancer Group Cologne, Center for Integrated Oncology, University Hospital Cologne, Cologne, Germany
| | - Elisabeth Bitter
- Lung Cancer Group Cologne, Center for Integrated Oncology, University Hospital Cologne, Cologne, Germany
| | | | - Rieke Nila Fischer
- Lung Cancer Group Cologne, Center for Integrated Oncology, University Hospital Cologne, Cologne, Germany
| | - Anna Kron
- University Hospital Cologne, Cologne, Germany
| | - Ulrich Gerigk
- Evangelische Kliniken Johanniter-und Waldkrankenhaus Bonn GmbH, Bonn, Germany
| | - Jens Kern
- University Hospital Würzburg Comprehensive Cancer Center Mainfranken, Wuerzburg, Germany
| | | | - Winfried Randerath
- Krankenhaus Bethanien, Klinik für Pneumologie und Allergologie, Zentrum für Schlaf- und Beatmungsmedizin, Solingen, Germany
| | | | | | - Sabine Merkelbach-Bruse
- Institute for Pathology, University Hospital of Cologne, Center for Integrated Oncology, Cologne, Germany
| | - Reinhard Büttner
- University Hospital Cologne, Institute of Pathology, Cologne, Germany
| | - Matthias Scheffler
- Lung Cancer Group Cologne, Center for Integrated Oncology, University Hospital Cologne, Cologne, Germany
| | - Juergen Wolf
- Lung Cancer Group Cologne, Center for Integrated Oncology, University Hospital Cologne, Cologne, Germany
| |
Collapse
|
5
|
Michels S, Scheel AH, Scheffler M, Schultheis AM, Gautschi O, Aebersold F, Diebold J, Pall G, Rothschild S, Bubendorf L, Hartmann W, Heukamp L, Schildhaus HU, Fassunke J, Ihle MA, Künstlinger H, Heydt C, Fischer R, Nogovà L, Mattonet C, Hein R, Adams A, Gerigk U, Schulte W, Lüders H, Grohé C, Graeven U, Müller-Naendrup C, Draube A, Kambartel KO, Krüger S, Schulze-Olden S, Serke M, Engel-Riedel W, Kaminsky B, Randerath W, Merkelbach-Bruse S, Büttner R, Wolf J. Clinicopathological Characteristics of RET Rearranged Lung Cancer in European Patients. J Thorac Oncol 2016; 11:122-7. [PMID: 26762747 DOI: 10.1016/j.jtho.2015.09.016] [Citation(s) in RCA: 53] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2015] [Revised: 09/11/2015] [Accepted: 09/14/2015] [Indexed: 11/19/2022]
Abstract
INTRODUCTION Rearrangements of RET are rare oncogenic events in patients with non-small cell lung cancer (NSCLC). While the characterization of Asian patients suggests a predominance of nonsmokers of young age in this genetically defined lung cancer subgroup, little is known about the characteristics of non-Asian patients. We present the results of an analysis of a European cohort of patients with RET rearranged NSCLC. METHODS Nine hundred ninety-seven patients with KRAS/EGFR/ALK wildtype lung adenocarcinomas were analyzed using fluorescence in situ hybridization for RET fusions. Tumor specimens were molecularly profiled and clinicopathological characteristics of the patients were collected. RESULTS Rearrangements of RET were identified in 22 patients, with a prevalence of 2.2% in the KRAS/EGFR/ALK wildtype subgroup. Co-occurring genetic aberrations were detected in 10 patients, and the majority had mutations in TP53. The median age at diagnosis was 62 years (range, 39-80 years; mean ± SD, 61 ± 11.7 years) with a higher proportion of men (59% versus 41%). There was only a slight predominance of nonsmokers (54.5%) compared to current or former smokers (45.5%). CONCLUSIONS Patients with RET rearranged adenocarcinomas represent a rare and heterogeneous NSCLC subgroup. In some contrast to published data, we see a high prevalence of current and former smokers in our white RET cohort. The significance of co-occurring aberrations, so far, is unclear.
Collapse
Affiliation(s)
- Sebastian Michels
- Center for Integrated Oncology Köln Bonn, Cologne, Germany; Lung Cancer Group Cologne, Department I for Internal Medicine, University Hospital of Cologne, Cologne, Germany; Network Genomic Medicine, Cologne, Germany
| | - Andreas Hans Scheel
- Network Genomic Medicine, Cologne, Germany; Institute of Pathology, University Hospital of Cologne, Cologne, Germany
| | - Matthias Scheffler
- Center for Integrated Oncology Köln Bonn, Cologne, Germany; Lung Cancer Group Cologne, Department I for Internal Medicine, University Hospital of Cologne, Cologne, Germany; Network Genomic Medicine, Cologne, Germany
| | - Anne Maria Schultheis
- Network Genomic Medicine, Cologne, Germany; Institute of Pathology, University Hospital of Cologne, Cologne, Germany
| | - Oliver Gautschi
- Department for Medical Oncology, Lucerne Cantonal Hospital, Lucerne, Switzerland
| | | | - Joachim Diebold
- Institute of Pathology, Lucerne Cantonal Hospital, Lucerne, Switzerland
| | - Georg Pall
- Department for Internal Medicine, Haematology and Oncology, University Hospital Innsbruck, Innsbruck, Austria
| | - Sacha Rothschild
- Department for Oncology, University Hospital Basel, Basel, Switzerland
| | - Lukas Bubendorf
- Department for Cytopathology, University Hospital Basel, Basel, Switzerland
| | - Wolfgang Hartmann
- Gerhard-Domagk-Institute of Pathology, University Hospital of Münster, Münster, Germany
| | - Lukas Heukamp
- Network Genomic Medicine, Cologne, Germany; Institute of Pathology, University Hospital of Cologne, Cologne, Germany
| | | | - Jana Fassunke
- Network Genomic Medicine, Cologne, Germany; Institute of Pathology, University Hospital of Cologne, Cologne, Germany
| | - Michaela Angelika Ihle
- Network Genomic Medicine, Cologne, Germany; Institute of Pathology, University Hospital of Cologne, Cologne, Germany
| | - Helen Künstlinger
- Network Genomic Medicine, Cologne, Germany; Institute of Pathology, University Hospital of Cologne, Cologne, Germany
| | - Carina Heydt
- Network Genomic Medicine, Cologne, Germany; Institute of Pathology, University Hospital of Cologne, Cologne, Germany
| | - Rieke Fischer
- Center for Integrated Oncology Köln Bonn, Cologne, Germany; Lung Cancer Group Cologne, Department I for Internal Medicine, University Hospital of Cologne, Cologne, Germany; Network Genomic Medicine, Cologne, Germany
| | - Lucia Nogovà
- Center for Integrated Oncology Köln Bonn, Cologne, Germany; Lung Cancer Group Cologne, Department I for Internal Medicine, University Hospital of Cologne, Cologne, Germany; Network Genomic Medicine, Cologne, Germany
| | - Christian Mattonet
- Center for Integrated Oncology Köln Bonn, Cologne, Germany; Lung Cancer Group Cologne, Department I for Internal Medicine, University Hospital of Cologne, Cologne, Germany; Network Genomic Medicine, Cologne, Germany
| | - Rebecca Hein
- Institute of Medical Statistics, Informatics and Epidemiology, University Hospital of Cologne, Cologne, Germany
| | - Anne Adams
- Institute of Medical Statistics, Informatics and Epidemiology, University Hospital of Cologne, Cologne, Germany
| | - Ulrich Gerigk
- Thoracic Centre, Malteser Hospital Bonn/Rhein-Sieg, Bonn, Germany
| | - Wolfgang Schulte
- Departent for Pulmonology Cardiology and Allergology, Johanniter Hospital, Bonn, Germany
| | - Heike Lüders
- Evangelic Lung Clinic Berlin, Department of Pneumology, Berlin, Germany
| | - Christian Grohé
- Evangelic Lung Clinic Berlin, Department of Pneumology, Berlin, Germany
| | - Ullrich Graeven
- Department for Hematology, Oncology and Gastroenterology, Maria Hilf Hospital Mönchengladbach, Mönchengladbach, Germany
| | | | - Andreas Draube
- Department for Internal Medicine, St. Vinzenz Hospital Cologne, Cologne, Germany
| | - Karl-Otto Kambartel
- Department for Pulmonology and Allergology, Bethanien Hospital Moers, Moers, Germany
| | - Stefan Krüger
- Department for Pulmonology/Allergology/Sleep Medicine and Respiratory Care, Florence-Nightingale-Hospital, Düsseldorf, Germany
| | - Susanne Schulze-Olden
- Department for Pulmonology/Allergology/Sleep Medicine and Respiratory Care, Florence-Nightingale-Hospital, Düsseldorf, Germany
| | - Monika Serke
- Department for Pulmonology and Thoracic Oncology, Lung Clinic Hemer, Hemer, Germany
| | | | - Britta Kaminsky
- Clinic for Pulmonology and Allergology, Bethanien Hospital, Solingen, Germany
| | - Winfried Randerath
- Clinic for Pulmonology and Allergology, Bethanien Hospital, Solingen, Germany
| | - Sabine Merkelbach-Bruse
- Network Genomic Medicine, Cologne, Germany; Institute of Pathology, University Hospital of Cologne, Cologne, Germany
| | - Reinhard Büttner
- Network Genomic Medicine, Cologne, Germany; Institute of Pathology, University Hospital of Cologne, Cologne, Germany
| | - Jürgen Wolf
- Center for Integrated Oncology Köln Bonn, Cologne, Germany; Lung Cancer Group Cologne, Department I for Internal Medicine, University Hospital of Cologne, Cologne, Germany; Network Genomic Medicine, Cologne, Germany.
| |
Collapse
|
6
|
Scheffler M, Schultheis A, Teixido C, Michels S, Morales-Espinosa D, Viteri S, Hartmann W, Merkelbach-Bruse S, Fischer R, Schildhaus HU, Fassunke J, Sebastian M, Serke M, Kaminsky B, Randerath W, Gerigk U, Ko YD, Krüger S, Schnell R, Rothe A, Kropf-Sanchen C, Heukamp L, Rosell R, Büttner R, Wolf J. ROS1 rearrangements in lung adenocarcinoma: prognostic impact, therapeutic options and genetic variability. Oncotarget 2016; 6:10577-85. [PMID: 25868855 PMCID: PMC4496376 DOI: 10.18632/oncotarget.3387] [Citation(s) in RCA: 74] [Impact Index Per Article: 9.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/11/2015] [Accepted: 02/15/2015] [Indexed: 12/12/2022] Open
Abstract
Background While recent data show that crizotinib is highly effective in patients with ROS1 rearrangement, few data is available about the prognostic impact, the predictive value for different treatments, and the genetic heterogeneity of ROS1-positive patients. Patients and Methods 1137 patients with adenocarcinoma of the lung were analyzed regarding their ROS1 status. In positive cases, next-generation sequencing (NGS) was performed. Clinical characteristics, treatments and outcome of these patients were assessed. Overall survival (OS) was compared with genetically defined subgroups of ROS1-negative patients. Results 19 patients of 1035 evaluable (1.8%) had ROS1-rearrangement. The median OS has not been reached. Stage IV patients with ROS1-rearrangement had the best OS of all subgroups (36.7 months, p < 0.001). 9 of 14 (64.2%) patients had at least one response to chemotherapy. Estimated mean OS for patients receiving chemotherapy and crizotinib was 5.3 years. Ten patients with ROS1-rearrangement (52.6%) harbored additional aberrations. Conclusion ROS1-rearangement is not only a predictive marker for response to crizotinib, but also seems to be the one of the best prognostic molecular markers in NSCLC reported so far. In stage IV patients, response to chemotherapy was remarkable high and overall survival was significantly better compared to other subgroups including EGFR-mutated and ALK-fusion-positive NSCLC.
Collapse
Affiliation(s)
- Matthias Scheffler
- Center for Integrated Oncology Köln Bonn, Cologne, Germany.,Lung Cancer Group Cologne, Department I for Internal Medicine, University Hospital of Cologne, Cologne, Germany
| | - Anne Schultheis
- Center for Integrated Oncology Köln Bonn, Cologne, Germany.,Institute of Pathology, University Hospital of Cologne, Cologne, Germany
| | - Cristina Teixido
- Pangaea Biotech, Quirón Dexeus University Hospital, Barcelona, Spain
| | - Sebastian Michels
- Center for Integrated Oncology Köln Bonn, Cologne, Germany.,Lung Cancer Group Cologne, Department I for Internal Medicine, University Hospital of Cologne, Cologne, Germany
| | | | - Santiago Viteri
- Instituto Oncológico Dr Rosell, Quirón Dexeus University Hospital, Barcelona, Spain
| | - Wolfgang Hartmann
- Gerhard-Domagk-Institute of Pathology, University Hospital of Münster, Münster, Germany
| | - Sabine Merkelbach-Bruse
- Center for Integrated Oncology Köln Bonn, Cologne, Germany.,Institute of Pathology, University Hospital of Cologne, Cologne, Germany
| | - Rieke Fischer
- Center for Integrated Oncology Köln Bonn, Cologne, Germany.,Lung Cancer Group Cologne, Department I for Internal Medicine, University Hospital of Cologne, Cologne, Germany
| | | | - Jana Fassunke
- Center for Integrated Oncology Köln Bonn, Cologne, Germany.,Institute of Pathology, University Hospital of Cologne, Cologne, Germany
| | - Martin Sebastian
- Department of Hematology/Oncology, University Hospital of Frankfurt, Frankfurt, Germany
| | - Monika Serke
- Department for Pulmonology and Thoracic Oncology, Lung Clinic Hemer, Hemer, Germany
| | - Britta Kaminsky
- Clinic for Pneumology and Allergology Center for Sleep Medicine and Respiratory Care, Bethanien Hospital, Solingen, Germany
| | - Winfried Randerath
- Clinic for Pneumology and Allergology Center for Sleep Medicine and Respiratory Care, Bethanien Hospital, Solingen, Germany
| | - Ulrich Gerigk
- Thoracic Centre, Malteser Hospital Bonn/Rhein-Sieg, Bonn, Germany
| | - Yon-Dschun Ko
- Johanniter Hospital, Evangelical Clinics of Bonn, Bonn, Germany
| | - Stefan Krüger
- Clinic for Pneumology/Allergology/Sleep Medicine and Respiratory Care, Florence-Nightingale-Hospital, Düsseldorf, Germany
| | - Roland Schnell
- Practice for Internistic Oncology and Hematology, Frechen, Germany
| | - Achim Rothe
- Practice for Hematology and Oncology Mainka/Dietze/Rothe, Cologne, Germany
| | | | - Lukas Heukamp
- Center for Integrated Oncology Köln Bonn, Cologne, Germany.,Institute of Pathology, University Hospital of Cologne, Cologne, Germany
| | - Rafael Rosell
- Instituto Oncológico Dr Rosell, Quirón Dexeus University Hospital, Barcelona, Spain.,Cancer Biology and Precision Medicine Program, Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Spain.,Molecular Oncology Research (MORe) Foundation, Barcelona, Spain
| | - Reinhard Büttner
- Center for Integrated Oncology Köln Bonn, Cologne, Germany.,Institute of Pathology, University Hospital of Cologne, Cologne, Germany
| | - Jürgen Wolf
- Center for Integrated Oncology Köln Bonn, Cologne, Germany.,Lung Cancer Group Cologne, Department I for Internal Medicine, University Hospital of Cologne, Cologne, Germany
| |
Collapse
|
7
|
Scheffler M, Bos M, Gardizi M, König K, Michels S, Fassunke J, Heydt C, Künstlinger H, Ihle M, Ueckeroth F, Albus K, Serke M, Gerigk U, Schulte W, Töpelt K, Nogova L, Zander T, Engel-Riedel W, Stoelben E, Ko YD, Randerath W, Kaminsky B, Panse J, Becker C, Hellmich M, Merkelbach-Bruse S, Heukamp LC, Büttner R, Wolf J. PIK3CA mutations in non-small cell lung cancer (NSCLC): genetic heterogeneity, prognostic impact and incidence of prior malignancies. Oncotarget 2015; 6:1315-26. [PMID: 25473901 PMCID: PMC4359235 DOI: 10.18632/oncotarget.2834] [Citation(s) in RCA: 87] [Impact Index Per Article: 9.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/22/2014] [Accepted: 11/25/2014] [Indexed: 01/07/2023] Open
Abstract
Background: Somatic mutations of the PIK3CA gene have been described in non-small cell lung cancer (NSCLC), but limited data is available on their biological relevance. This study was performed to characterize PIK3CA-mutated NSCLC clinically and genetically. Patients and methods: Tumor tissue collected consecutively from 1144 NSCLC patients within a molecular screening network between March 2010 and March 2012 was analyzed for PIK3CA mutations using dideoxy-sequencing and next-generation sequencing (NGS). Clinical, pathological, and genetic characteristics of PIK3CA-mutated patients are described and compared with a control group of PIK3CA-wildtype patients. Results: Among the total cohort of 1144 patients we identified 42 (3.7%) patients with PIK3CA mutations in exon 9 and exon 20. These mutations were found with a higher frequency in sqamous cell carcinoma (8.9%) compared to adenocarcinoma (2.9%, p<0.001). The most common PIK3CA mutation was exon 9 E545K. The majority of patients (57.1%) had additional oncogenic driver aberrations. With the exception of EGFR-mutated patients, non of the genetically defined subgroups in this cohort had a significantly better median overall survival. Further, PIK3CA-mutated patients had a significantly higher incidence of malignancy prior to lung cancer (p<0.001). Conclusion: PIK3CA-mutated NSCLC represents a clinically and genetically heterogeneous subgroup in adenocarcinomas as well as in squamous cell carcinomas with a higher prevalence of these mutations in sqamous cell carcinoma. PIK3CA mutations have no negative impact on survival after surgery or systemic therapy. However, PIK3CA mutated lung cancer frequently develops in patients with prior malignancies.
Collapse
Affiliation(s)
- Matthias Scheffler
- Center for Integrated Oncology Köln Bonn, Cologne, Germany.,Lung Cancer Group Cologne, Department I for Internal Medicine, University Hospital of Cologne, Cologne, Germany
| | - Marc Bos
- Center for Integrated Oncology Köln Bonn, Cologne, Germany.,Lung Cancer Group Cologne, Department I for Internal Medicine, University Hospital of Cologne, Cologne, Germany
| | - Masyar Gardizi
- Center for Integrated Oncology Köln Bonn, Cologne, Germany.,Lung Cancer Group Cologne, Department I for Internal Medicine, University Hospital of Cologne, Cologne, Germany
| | - Katharina König
- Center for Integrated Oncology Köln Bonn, Cologne, Germany.,Institute of Pathology, University Hospital of Cologne, Cologne, Germany
| | - Sebastian Michels
- Center for Integrated Oncology Köln Bonn, Cologne, Germany.,Lung Cancer Group Cologne, Department I for Internal Medicine, University Hospital of Cologne, Cologne, Germany
| | - Jana Fassunke
- Center for Integrated Oncology Köln Bonn, Cologne, Germany.,Institute of Pathology, University Hospital of Cologne, Cologne, Germany
| | - Carina Heydt
- Center for Integrated Oncology Köln Bonn, Cologne, Germany.,Institute of Pathology, University Hospital of Cologne, Cologne, Germany
| | - Helen Künstlinger
- Center for Integrated Oncology Köln Bonn, Cologne, Germany.,Institute of Pathology, University Hospital of Cologne, Cologne, Germany
| | - Michaela Ihle
- Center for Integrated Oncology Köln Bonn, Cologne, Germany.,Institute of Pathology, University Hospital of Cologne, Cologne, Germany
| | - Frank Ueckeroth
- Center for Integrated Oncology Köln Bonn, Cologne, Germany.,Institute of Pathology, University Hospital of Cologne, Cologne, Germany
| | - Kerstin Albus
- Center for Integrated Oncology Köln Bonn, Cologne, Germany.,Institute of Pathology, University Hospital of Cologne, Cologne, Germany
| | - Monika Serke
- Department for Pulmonology and Thoracic Oncology, Lung Clinic Hemer, Hemer, Germany
| | - Ulrich Gerigk
- Clinic for Hematology, Oncology and Palliative Care, Malteser Hospital, Bonn, Germany
| | - Wolfgang Schulte
- Clinic for Hematology, Oncology and Palliative Care, Malteser Hospital, Bonn, Germany
| | - Karin Töpelt
- Center for Integrated Oncology Köln Bonn, Cologne, Germany.,Lung Cancer Group Cologne, Department I for Internal Medicine, University Hospital of Cologne, Cologne, Germany
| | - Lucia Nogova
- Center for Integrated Oncology Köln Bonn, Cologne, Germany.,Lung Cancer Group Cologne, Department I for Internal Medicine, University Hospital of Cologne, Cologne, Germany
| | - Thomas Zander
- Center for Integrated Oncology Köln Bonn, Cologne, Germany.,Gastrointestinal Cancer Group Cologne, Department I for Internal Medicine, University Hospital of Cologne, Cologne, Germany
| | | | - Erich Stoelben
- Lung Clinic Merheim, Hospital of Cologne, Cologne, Germany
| | - Yon-Dschun Ko
- Johanniter Hospital, Evangelical Clinics of Bonn, Bonn, Germany
| | - Winfried Randerath
- Clinic for Pneumology and Allergology Center for Sleep Medicine and Respiratory Care, Bethanien Hospital, Solingen, Germany
| | - Britta Kaminsky
- Clinic for Pneumology and Allergology Center for Sleep Medicine and Respiratory Care, Bethanien Hospital, Solingen, Germany
| | - Jens Panse
- Department of Medicine IV, University Hospital RWTH Aachen, Aachen, Germany
| | - Carolin Becker
- Department of Medicine IV, University Hospital RWTH Aachen, Aachen, Germany
| | - Martin Hellmich
- Institute of Medical Statistics, Informatics, and Epidemiology, University of Cologne, Cologne, Germany
| | - Sabine Merkelbach-Bruse
- Center for Integrated Oncology Köln Bonn, Cologne, Germany.,Institute of Pathology, University Hospital of Cologne, Cologne, Germany
| | - Lukas C Heukamp
- Center for Integrated Oncology Köln Bonn, Cologne, Germany.,Institute of Pathology, University Hospital of Cologne, Cologne, Germany
| | - Reinhard Büttner
- Center for Integrated Oncology Köln Bonn, Cologne, Germany.,Institute of Pathology, University Hospital of Cologne, Cologne, Germany
| | - Jürgen Wolf
- Center for Integrated Oncology Köln Bonn, Cologne, Germany.Lung Cancer Group Cologne, Department I for Internal Medicine, University Hospital of Cologne, Cologne, Germany
| |
Collapse
|
8
|
Gogl L, Scheffler M, Ihle M, Michels S, Fischer R, Serke M, Gerigk U, Wömpner C, Krüger S, Kaminsky B, Schulte W, Höffken G, Merkelbach-Bruse S, Büttner R, Wolf J. 3131 Clinical and molecular characteristics of non-small cell lung cancer in patients harboring CTNNB1 mutations. Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)31772-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
9
|
Eisert A, Scheffler M, Michels SYF, Schultheis AM, Frank R, Koenig K, Merkelbach-Bruse S, Fischer R, Serke MH, Ko YD, Gerigk U, Geist T, Heukamp LC, Büttner R, Wolf J. Genetic variability and clinical presentation of patients with non-small cell lung cancer (NSCLC) harboring MET-amplifications. J Clin Oncol 2015. [DOI: 10.1200/jco.2015.33.15_suppl.8088] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- Anna Eisert
- Lung Cancer Group Cologne, Department I of Internal Medicine, University Hospital of Cologne, Center for Integrated Oncology (CIO) Köln Bonn, Cologne, Germany
| | - Matthias Scheffler
- Lung Cancer Group Cologne, Department I of Internal Medicine and Center for Integrated Oncology Cologne Bonn, University Hospital Cologne, Cologne, Germany
| | - Sebastian Yves Friedrich Michels
- Lung Cancer Group Cologne, Department I of Internal Medicine and Center of Integrated Oncology Cologne Bonn, University Hospital Cologne, Cologne, Germany
| | - Anne Maria Schultheis
- University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA
| | - Rieke Frank
- Lung Cancer Group Cologne, Department I of Internal Medicine, University Hospital of Cologne, Center for Integrated Oncology (CIO) Köln Bonn, Cologne, Germany
| | - Katharina Koenig
- Institute of Pathology, University Hospital Cologne and Center for Integrated Oncology Köln-Bonn, Cologne, Germany
| | - Sabine Merkelbach-Bruse
- Institute for Pathology, University Hospital Cologne, Center for Integrated Oncology, Cologne, Germany, Cologne, Germany
| | - Rieke Fischer
- Lung Cancer Group Cologne, Department I of Internal Medicine and Center for Integrated Oncology Cologne Bonn, University Hospital of Cologne, Cologne, Germany
| | | | | | - Ulrich Gerigk
- Evangelische Kliniken Johanniter-und Waldkrankenhaus Bonn GmbH, Bonn, Germany
| | - Thomas Geist
- Klinik für Pneumologie, Allergologie, Schlaf- und Beatmungsmedizin, Kaiserswerther Diakonie, Düsseldorf, Germany
| | - Lukas Carl Heukamp
- Institute of Pathology, University Hospital Cologne and Center for Integrated Oncology Köln-Bonn, Cologne, Germany
| | - Reinhard Büttner
- University Hospital Cologne, Institute of Pathology, Cologne, Germany
| | - Juergen Wolf
- Department I of Internal Medicine and Center of Integrated Oncology Cologne Bonn, University Hospital Cologne, Cologne, Germany
| |
Collapse
|
10
|
Frank R, Scheffler M, Michels SYF, Eisert A, Fischer R, Koenig K, Merkelbach-Bruse S, Serke MH, Ko YD, Gerigk U, Geist T, Heukamp LC, Büttner R, Wolf J. KEAP1-mutations in patients with non-small cell lung cancer (NSCLC). J Clin Oncol 2015. [DOI: 10.1200/jco.2015.33.15_suppl.8097] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- Rieke Frank
- Lung Cancer Group Cologne, Department I of Internal Medicine, University Hospital of Cologne, Center for Integrated Oncology (CIO) Köln Bonn, Cologne, Germany
| | - Matthias Scheffler
- Lung Cancer Group Cologne, Department I of Internal Medicine and Center for Integrated Oncology Cologne Bonn, University Hospital Cologne, Cologne, Germany
| | - Sebastian Yves Friedrich Michels
- Lung Cancer Group Cologne, Department I of Internal Medicine and Center of Integrated Oncology Cologne Bonn, University Hospital Cologne, Cologne, Germany
| | - Anna Eisert
- Lung Cancer Group Cologne, Department I of Internal Medicine, University Hospital of Cologne, Center for Integrated Oncology (CIO) Köln Bonn, Cologne, Germany
| | - Rieke Fischer
- Lung Cancer Group Cologne, Department I of Internal Medicine and Center for Integrated Oncology Cologne Bonn, University Hospital of Cologne, Cologne, Germany
| | - Katharina Koenig
- Institute of Pathology, University Hospital Cologne and Center for Integrated Oncology Köln-Bonn, Cologne, Germany
| | - Sabine Merkelbach-Bruse
- Institute for Pathology, University Hospital Cologne, Center for Integrated Oncology, Cologne, Germany, Cologne, Germany
| | | | | | - Ulrich Gerigk
- Evangelische Kliniken Johanniter-und Waldkrankenhaus Bonn GmbH, Bonn, Germany
| | - Thomas Geist
- Klinik für Pneumologie, Allergologie, Schlaf- und Beatmungsmedizin, Kaiserswerther Diakonie, Düsseldorf, Germany
| | - Lukas Carl Heukamp
- Institute of Pathology, University Hospital Cologne and Center for Integrated Oncology Köln-Bonn, Cologne, Germany
| | - Reinhard Büttner
- University Hospital Cologne, Institute of Pathology, Cologne, Germany
| | - Juergen Wolf
- Department I of Internal Medicine and Center of Integrated Oncology Cologne Bonn, University Hospital Cologne, Cologne, Germany
| |
Collapse
|
11
|
Scheffler M, Schultheis AM, Teixido C, Michels SYF, Morales-Espinosa D, Viteri S, Merkelbach-Bruse S, Fischer R, Fassunke J, Sebastian M, Serke MH, Randerath W, Gerigk U, Ko YD, Krüger S, Schnell R, Rothe A, Rosell R, Büttner R, Wolf J. ROS1 rearrangement in non-small cell lung cancer (NSCLC): Prognostic and predicitve impact and genetic variability. J Clin Oncol 2015. [DOI: 10.1200/jco.2015.33.15_suppl.8066] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- Matthias Scheffler
- Lung Cancer Group Cologne, Department I of Internal Medicine and Center for Integrated Oncology Cologne Bonn, University Hospital Cologne, Cologne, Germany
| | - Anne Maria Schultheis
- University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA
| | | | - Sebastian Yves Friedrich Michels
- Lung Cancer Group Cologne, Department I of Internal Medicine and Center of Integrated Oncology Cologne Bonn, University Hospital Cologne, Cologne, Germany
| | - Daniela Morales-Espinosa
- Instituto Oncologico Dr Rosell, Translational Research laboratory. Quiron-Dexeus University Hospital, Barcelona, Spain
| | | | - Sabine Merkelbach-Bruse
- Institute for Pathology, University Hospital Cologne, Center for Integrated Oncology, Cologne, Germany, Cologne, Germany
| | - Rieke Fischer
- Lung Cancer Group Cologne, Department I of Internal Medicine and Center for Integrated Oncology Cologne Bonn, University Hospital of Cologne, Cologne, Germany
| | - Jana Fassunke
- Institute for Pathology, University Hospital Cologne, Center for Integrated Oncology, Cologne, Germany, Cologne, Germany
| | - Martin Sebastian
- Medizinische Klinik II Hämatologie/Onkologie, Rheumatologie, Infektiologie, HIV Klinikum der J.W. Goethe-Universität Frankfurt, Frankfurt Am Main, Germany
| | | | - Winfried Randerath
- Krankenhaus Bethanien, Klinik für Pneumologie und Allergologie, Zentrum für Schlaf- und Beatmungsmedizin, Solingen, Germany
| | - Ulrich Gerigk
- Evangelische Kliniken Johanniter-und Waldkrankenhaus Bonn GmbH, Bonn, Germany
| | | | | | - Roland Schnell
- Praxis internistischer Onkologie und Hamatologie, Frechen, Germany
| | - Achim Rothe
- Formerly of University Hospital of Cologne, Department of Internal Medicine I, Cologne, Germany
| | - Rafael Rosell
- Cancer Biology and Precision Medicine Program, Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain
| | - Reinhard Büttner
- University Hospital Cologne, Institute of Pathology, Cologne, Germany
| | - Juergen Wolf
- Department I of Internal Medicine and Center of Integrated Oncology Cologne Bonn, University Hospital Cologne, Cologne, Germany
| | | |
Collapse
|
12
|
Gogl L, Scheffler M, Michaela I, Michels SYF, Fischer R, Serke MH, Gerigk U, Wompner C, Krüger S, Kaminsky B, Schulte W, Höffken G, Merkelbach-Bruse S, Büttner R, Wolf J. Clinical and molecular characteristics of non-small cell lung cancer in patients harboring CTNNB1 mutations. J Clin Oncol 2015. [DOI: 10.1200/jco.2015.33.15_suppl.8098] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- Leonie Gogl
- Lung Cancer Group Cologne, Departement I of Internal Medicine, University Hospital of Cologne, Center for Integrated oncology (CIO) Köln Bonn, Cologne, Germany
| | - Matthias Scheffler
- Lung Cancer Group Cologne, Department I of Internal Medicine and Center for Integrated Oncology Cologne Bonn, University Hospital Cologne, Cologne, Germany
| | - Ihle Michaela
- Institute of Pathology, University of Cologne, Cologne, Germany
| | - Sebastian Yves Friedrich Michels
- Lung Cancer Group Cologne, Department I of Internal Medicine and Center of Integrated Oncology Cologne Bonn, University Hospital Cologne, Cologne, Germany
| | - Rieke Fischer
- Lung Cancer Group Cologne, Department I of Internal Medicine and Center for Integrated Oncology Cologne Bonn, University Hospital of Cologne, Cologne, Germany
| | | | - Ulrich Gerigk
- Evangelische Kliniken Johanniter-und Waldkrankenhaus Bonn GmbH, Bonn, Germany
| | - Claudia Wompner
- Lung Cancer Group Cologne, Departement I of Internal Medicine, University Hospital of Cologne, Center for Integrated Oncology (CIO), Cologne, Germany
| | | | | | | | | | - Sabine Merkelbach-Bruse
- Institute for Pathology, University Hospital Cologne, Center for Integrated Oncology, Cologne, Germany, Cologne, Germany
| | - Reinhard Büttner
- University Hospital Cologne, Institute of Pathology, Cologne, Germany
| | - Juergen Wolf
- Department I of Internal Medicine and Center of Integrated Oncology Cologne Bonn, University Hospital Cologne, Cologne, Germany
| |
Collapse
|
13
|
Schildhaus HU, Schultheis AM, Rüschoff J, Binot E, Merkelbach-Bruse S, Fassunke J, Schulte W, Ko YD, Schlesinger A, Bos M, Gardizi M, Engel-Riedel W, Brockmann M, Serke M, Gerigk U, Hekmat K, Frank KF, Reiser M, Schulz H, Krüger S, Stoelben E, Zander T, Wolf J, Buettner R. MET amplification status in therapy-naïve adeno- and squamous cell carcinomas of the lung. Clin Cancer Res 2014; 21:907-15. [PMID: 25492085 DOI: 10.1158/1078-0432.ccr-14-0450] [Citation(s) in RCA: 140] [Impact Index Per Article: 14.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
PURPOSE MET is a potential therapeutic target in lung cancer and both MET tyrosine kinase inhibitors and monoclonal antibodies have entered clinical trials. MET signaling can be activated by various mechanisms, including gene amplification. In this study, we aimed to investigate MET amplification status in adeno- and squamous cell carcinomas of the lung. We propose clearly defined amplification scores and provide epidemiologic data on MET amplification in lung cancer. EXPERIMENTAL DESIGN We evaluated the prevalence of increased MET gene copy numbers in 693 treatment-naïve cancers by FISH, defined clear cutoff criteria, and correlated FISH results to MET IHC. RESULTS Two thirds (67%) of lung cancers do not have gains in MET gene copy numbers, whereas 3% show a clear-cut high-level amplification (MET/centromer7 ratio ≥2.0 or average gene copy number per nucleus ≥6.0 or ≥10% of tumor cells containing ≥15 MET copies). The remaining cases can be subdivided into intermediate- (6%) and low-level gains (24%). Importantly, MET amplifications occur at equal frequencies in squamous and adenocarcinomas without or with EGFR or KRAS mutations. CONCLUSION MET amplification is not a mutually exclusive genetic event in therapy-naïve non-small cell lung cancer. Our data suggest that it might be useful to determine MET amplification (i) before EGFR inhibitor treatment to identify possible primary resistance to anti-EGFR treatment, and (ii) to select cases that harbor KRAS mutations additionally to MET amplification and, thus, may not benefit from MET inhibition. Furthermore, our study provides comprehensive epidemiologic data for upcoming trials with various MET inhibitors.
Collapse
Affiliation(s)
- Hans-Ulrich Schildhaus
- Institute of Pathology, University Hospital Cologne, Cologne, Germany. Center for Integrated Oncology, University Hospital Cologne, Cologne, Germany. Institute of Pathology, University Hospital Göttingen, Göttingen, Germany.
| | - Anne M Schultheis
- Institute of Pathology, University Hospital Cologne, Cologne, Germany. Center for Integrated Oncology, University Hospital Cologne, Cologne, Germany
| | - Josef Rüschoff
- Institute of Pathology Nordhessen, Kassel, Germany. Targos Molecular Pathology, Kassel, Germany
| | - Elke Binot
- Institute of Pathology, University Hospital Cologne, Cologne, Germany. Center for Integrated Oncology, University Hospital Cologne, Cologne, Germany
| | - Sabine Merkelbach-Bruse
- Institute of Pathology, University Hospital Cologne, Cologne, Germany. Center for Integrated Oncology, University Hospital Cologne, Cologne, Germany
| | - Jana Fassunke
- Institute of Pathology, University Hospital Cologne, Cologne, Germany. Center for Integrated Oncology, University Hospital Cologne, Cologne, Germany
| | - Wolfgang Schulte
- Thoraxzentrum im Malteser Krankenhaus Bonn/Rhein-Sieg, Bonn, Germany
| | - Yon-Dschun Ko
- Johanniter-Krankenhaus, Evangelische Kliniken Bonn GmbH, Bonn, Germany
| | | | - Marc Bos
- Center for Integrated Oncology, University Hospital Cologne, Cologne, Germany. Department I of Internal Medicine and Centre of Integrated Oncology Köln-Bonn, University of Cologne, Cologne, Germany
| | - Masyar Gardizi
- Center for Integrated Oncology, University Hospital Cologne, Cologne, Germany. Department I of Internal Medicine and Centre of Integrated Oncology Köln-Bonn, University of Cologne, Cologne, Germany
| | | | - Michael Brockmann
- Institute of Pathology, Kliniken der Stadt Köln GmbH, Cologne, Germany
| | | | - Ulrich Gerigk
- Thoraxzentrum im Malteser Krankenhaus Bonn/Rhein-Sieg, Bonn, Germany
| | - Khosro Hekmat
- Department of Cardiothoracic Surgery, University of Cologne, Cologne, Germany
| | - Konrad F Frank
- Department III of Internal Medicine, University of Cologne, Cologne, Germany
| | - Marcel Reiser
- PIOH-Praxis Internistischer Onkologie und Hämatologie Köln, Cologne, Germany
| | - Holger Schulz
- PIOH-Praxis Internistischer Onkologie und Hämatologie Frechen, Frechen, Germany
| | - Stefan Krüger
- Florence Nightingale Krankenhaus Düsseldorf Kaiserswerth, Düsseldorf, Germany
| | - Erich Stoelben
- Lungenklinik Merheim, Kliniken der Stadt Köln GmbH, Cologne, Germany
| | - Thomas Zander
- Department I of Internal Medicine and Centre of Integrated Oncology Köln-Bonn, University of Cologne, Cologne, Germany. NGM, Network Genomic Medicine and GCGC, Gastrointestinal Cancer Group Cologne, Germany
| | - Jürgen Wolf
- Center for Integrated Oncology, University Hospital Cologne, Cologne, Germany. Department I of Internal Medicine and Centre of Integrated Oncology Köln-Bonn, University of Cologne, Cologne, Germany
| | - Reinhard Buettner
- Institute of Pathology, University Hospital Cologne, Cologne, Germany. Center for Integrated Oncology, University Hospital Cologne, Cologne, Germany. Targos Molecular Pathology, Kassel, Germany
| |
Collapse
|
14
|
Frank R, Scheffler M, Michels S, König K, Merkelbach-Bruse S, Serke M, Ko Y, Gerigk U, Geist T, Heukamp L, Büttner R, Wolf J. Occurrence and Characteristics of Keap1-Mutations in Patients with Non-Small Cell Lung Cancer (Nsclc). Ann Oncol 2014. [DOI: 10.1093/annonc/mdu349.93] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
15
|
Michels S, Schultheis A, Scheffler M, Rosner T, Merkelbach-Bruse S, Heukamp L, Engel-Riedel W, Serke M, Krüger S, Benedikter J, Gerigk U, Schulte W, Draube A, Ko Y, Büttner R, Wolf J. Ret Translocation in Adenocarcinoma of the Lung. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu349.87] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
16
|
Eisert A, Scheffler M, Michels S, Schultheis A, König K, Merkelbach-Bruse S, Serke M, Ko Y, Gerigk U, Geist T, Heukamp L, Büttner R, Wolf J. Genetic Variability and Clinical Presentation of Patients with Non-Small Cell Lung Cancer (Nsclc) Harboring Met-Amplifications. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu349.95] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
17
|
Göke F, Franzen A, Menon R, Goltz D, Kirsten R, Boehm D, Vogel W, Göke A, Scheble V, Ellinger J, Gerigk U, Fend F, Wagner P, Schroeck A, Perner S. Rationale for treatment of metastatic squamous cell carcinoma of the lung using fibroblast growth factor receptor inhibitors. Chest 2013; 142:1020-1026. [PMID: 22499828 DOI: 10.1378/chest.11-2943] [Citation(s) in RCA: 42] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022] Open
Abstract
BACKGROUND We previously identified amplification of the fibroblast growth factor receptor 1 gene (FGFR1) as a potential therapeutic target for small-molecule inhibitor therapy in squamous cell lung cancer (L-SCC). Currently, clinical phase I trials are underway to examine whether patients with FGFR1-amplified L-SCC benefit from a targeted therapy approach using small-molecule inhibitors. Because most patients with lung cancer present with metastatic disease, we investigated whether lymph node metastases in L-SCC share the FGFR1 amplification status of their corresponding primary tumor. METHODS The study cohort consisted of 72 patients with L-SCC, 39 with regional lymph node metastases. Tissue microarrays were constructed from formalin-fixed, paraffin-embedded tissue of the primary tumors and, where present, of the corresponding lymph node metastasis. A biotin-labeled target probe spanning the FGFR1 locus (8p11.22-23) was used to determine the FGFR1 amplification status by fluorescence in situ hybridization. RESULTS FGFR1 amplification was detected in 16% (12 of 72) of all primary L-SCCs. In metastatic tumors, 18% (seven of 39) of the lymph node metastases displayed FGFR1 amplification with an exact correlation of FGFR1 amplification status between tumor and metastatic tissue. CONCLUSIONS FGFR1 amplification is a common genetic event occurring at a frequency of 16% in L-SCCs. Moreover, lymph node metastases derived from FGFR1-amplified L-SCCs also exhibit FGFR1 amplification. Therefore, we suggest that the FGFR1 amplification is a clonal event in tumor progression. Beyond this biologically relevant observation, the findings carry potential therapeutic implications in that small-molecule inhibitors may be applicable to the treatment of a subset of patients with metastatic L-SCC.
Collapse
Affiliation(s)
- Friederike Göke
- Institute of Pathology, Affiliated Malteser Hospital, University Hospital of Bonn, Bonn, Germany; Institute of Prostate Cancer Research, Affiliated Malteser Hospital, University Hospital of Bonn, Bonn, Germany
| | - Alina Franzen
- Institute of Pathology, Affiliated Malteser Hospital, University Hospital of Bonn, Bonn, Germany; Institute of Prostate Cancer Research, Affiliated Malteser Hospital, University Hospital of Bonn, Bonn, Germany
| | - Roopika Menon
- Institute of Pathology, Affiliated Malteser Hospital, University Hospital of Bonn, Bonn, Germany; Institute of Prostate Cancer Research, Affiliated Malteser Hospital, University Hospital of Bonn, Bonn, Germany
| | - Diane Goltz
- Institute of Pathology, Affiliated Malteser Hospital, University Hospital of Bonn, Bonn, Germany
| | - Robert Kirsten
- Institute of Prostate Cancer Research, Affiliated Malteser Hospital, University Hospital of Bonn, Bonn, Germany
| | - Diana Boehm
- Institute of Prostate Cancer Research, Affiliated Malteser Hospital, University Hospital of Bonn, Bonn, Germany
| | - Wenzel Vogel
- Institute of Prostate Cancer Research, Affiliated Malteser Hospital, University Hospital of Bonn, Bonn, Germany
| | - Antonia Göke
- Institute of Prostate Cancer Research, Affiliated Malteser Hospital, University Hospital of Bonn, Bonn, Germany
| | - Veit Scheble
- Department of Hematology and Oncology, University Hospital of Tuebingen, Tuebingen, Germany
| | - Joerg Ellinger
- Department of Urology, Affiliated Malteser Hospital, University Hospital of Bonn, Bonn, Germany
| | - Ulrich Gerigk
- Department of Thorax Surgery, Affiliated Malteser Hospital, University Hospital of Bonn, Bonn, Germany
| | - Falko Fend
- Institute of Pathology, University Hospital of Tuebingen, Tuebingen, Germany
| | - Patrick Wagner
- Division of Surgical Oncology, University of Pittsburgh Medical Center, Pittsburgh, PA
| | - Andreas Schroeck
- Institute of Prostate Cancer Research, Affiliated Malteser Hospital, University Hospital of Bonn, Bonn, Germany; Department of Head and Neck Surgery, Affiliated Malteser Hospital, University Hospital of Bonn, Bonn, Germany
| | - Sven Perner
- Institute of Pathology, Affiliated Malteser Hospital, University Hospital of Bonn, Bonn, Germany; Institute of Prostate Cancer Research, Affiliated Malteser Hospital, University Hospital of Bonn, Bonn, Germany.
| |
Collapse
|
18
|
Zander T, Heukamp LC, Bos MCA, Fassunke J, Mattonet C, Merkelbach-Bruse S, Ko YD, Schlesinger A, Brockmann M, Serke M, Gerigk U, Hekmat K, Engel-Riedel W, Stoelben E, Reiser M, Schulz H, Schmitz SH, Frank K, Buettner R, Wolf J. Regional screening network for characterization of the molecular epidemiology of non-small cell lung cancer (NSCLC) and implementation of personalized treatment. J Clin Oncol 2012. [DOI: 10.1200/jco.2012.30.18_suppl.cra10529] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
CRA10529 Background: Personalized treatment of genetically stratified subgroups has the potential to substantially improve outcome in NSCLC. A major challenge now is to implement high-quality molecular diagnostics and personalized treatment strategies in routine clinical practice also outside of highly specialized academic centers. Methods: We have established a molecular screening network in the catchment area of our comprehensive cancer center encompassing about 2.5 million inhabitants in March 2010 after review of the local ethics committee (10-242). Lung adenocarcinoma (AD) was screened centrally for ALK translocations, mutations in KRAS, EGFR, BRAF and PIK3CA and for amplification of ERBB2. Squamous cell carcinoma (SQ) was analyzed for FGFR1 amplifications. Results: 2032 NSCLC samples were acquired of which 1782 in the Cologne-Bonn area indicating a capture rate of 60-70% of all NSCLC samples in the area. Material was suitable for molecular analysis in 77%. Distribution of histological subtypes was as expected (AD 63.4%, SQ 26.7, large cell carcinoma 1.4%, adenosquamous cell carcinoma 1.8%, carcinoid 0.1%, NSCLC NOS 6.7%. In AD the following frequencies of genetic lesions were detected: KRAS (32%), EGFR (13%), ALK (3%), BRAF (2%), PIK3CA (2%), ERBB2 (2%). EGFR mutations were highly enriched in the lepidic and micropapillary subtype of AD (30-32%), whereas the solid subtype only harboured a very small amount of the tested oncogenic lesions. In SQ FGFR1 amplification was detected in 78/500. Overall 40% of all NSCLC samples harboured potentially tractable oncogenic lesions. All patients with ALK translocations received crizotinib when clinically indicated. 75% of the stage IIIB/IV patients with activating EGFR mutations received EGFR-TKI treatment. In addition, clinical trials have been initiated to provide personalized treatment options to all patients with tractable genetic lesions. Conclusions: High-quality molecular diagnostics and identification of patients for personalized treatment approaches is feasible in daily clinical routine for the majority of diagnostic samples also in a non-academic setting.
Collapse
Affiliation(s)
- Thomas Zander
- Lung Cancer Group Cologne, Center for Integrated Oncology, University Hospital Cologne, Cologne, Germany
| | - Lukas Carl Heukamp
- Institute of Pathology, University Hospital Cologne and Center for Integrated Oncology Köln-Bonn, Cologne, Germany
| | - Marc Christiaan Allardt Bos
- Department I of Internal Medicine and Center for Integrated Oncology Köln-Bonn, University of Cologne, Cologne, Germany
| | - Jana Fassunke
- Institute for Pathology, University Hospital Cologne, Center for Integrated Oncology, Cologne, Germany, Cologne, Germany
| | - Christian Mattonet
- Lung Cancer Group Cologne, Center for Integrated Oncology, University Hospital Cologne, Cologne, Germany
| | - Sabine Merkelbach-Bruse
- Institute for Pathology, University Hospital Cologne, Center for Integrated Oncology, Cologne, Germany, Cologne, Germany
| | | | | | - Michael Brockmann
- Institute for Pathology, Hospital of the City of Cologne, Merheim, University Hospital Witten/Herdecke, Cologne, Germany
| | | | - Ulrich Gerigk
- Evangelische Kliniken Johanniter-und Waldkrankenhaus Bonn GmbH, Bonn, Germany
| | - Khosro Hekmat
- Department of Cardiothroracic Surgery, University of Cologne, Cologne, Germany
| | | | - Erich Stoelben
- Lung Clinic, Hospital of the City of Cologne, Cologne, Germany
| | - Marcel Reiser
- Pioh, private practice for hematology and oncology, Frechen/Cologne, Germany, Cologne, Germany
| | - Holger Schulz
- Pioh, private practice for hematology and oncology, Cologne, Germany
| | | | - Konrad Frank
- Department III of Internal Medicine, University of Cologne, Cologne, Germany
| | - Reinhard Buettner
- Institute of Pathology, University Hospital Cologne and Center for Integrated Oncology Köln-Bonn, Cologne, Germany
| | - Juergen Wolf
- Lung Cancer Group Cologne, Center for Integrated Oncology, University Hospital Cologne, Koeln, Germany
| |
Collapse
|
19
|
Zander T, Heukamp LC, Bos MCA, Fassunke J, Mattonet C, Merkelbach-Bruse S, Ko YD, Schlesinger A, Brockmann M, Serke M, Gerigk U, Hekmat K, Engel-Riedel W, Stoelben E, Reiser M, Schulz H, Schmitz SH, Frank K, Buettner R, Wolf J. Regional screening network for characterization of the molecular epidemiology of non-small cell lung cancer (NSCLC) and implementation of personalized treatment. J Clin Oncol 2012. [DOI: 10.1200/jco.2012.30.15_suppl.cra10529] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
CRA10529 The full, final text of this abstract will be available at abstract.asco.org at 12:01 AM (EDT) on Monday, June 4, 2012, and in the Annual Meeting Proceedings online supplement to the June 20, 2012, issue of Journal of Clinical Oncology. Onsite at the Meeting, this abstract will be printed in the Monday edition of ASCO Daily News.
Collapse
Affiliation(s)
- Thomas Zander
- Lung Cancer Group Cologne, Center for Integrated Oncology, University Hospital Cologne, Cologne, Germany
| | - Lukas Carl Heukamp
- Institute of Pathology, University Hospital Cologne and Center for Integrated Oncology Köln-Bonn, Cologne, Germany
| | - Marc Christiaan Allardt Bos
- Department I of Internal Medicine and Center for Integrated Oncology Köln-Bonn, University of Cologne, Cologne, Germany
| | - Jana Fassunke
- Institute for Pathology, University Hospital Cologne, Center for Integrated Oncology, Cologne, Germany, Cologne, Germany
| | - Christian Mattonet
- Lung Cancer Group Cologne, Center for Integrated Oncology, University Hospital Cologne, Cologne, Germany
| | - Sabine Merkelbach-Bruse
- Institute for Pathology, University Hospital Cologne, Center for Integrated Oncology, Cologne, Germany, Cologne, Germany
| | | | | | - Michael Brockmann
- Institute for Pathology, Hospital of the City of Cologne, Merheim, University Hospital Witten/Herdecke, Cologne, Germany
| | | | - Ulrich Gerigk
- Evangelische Kliniken Johanniter-und Waldkrankenhaus Bonn GmbH, Bonn, Germany
| | - Khosro Hekmat
- Department of Cardiothroracic Surgery, University of Cologne, Cologne, Germany
| | | | - Erich Stoelben
- Lung Clinic, Hospital of the City of Cologne, Cologne, Germany
| | - Marcel Reiser
- Pioh, private practice for hematology and oncology, 50226 Frechen/Cologne, Germany, Cologne, Germany
| | - Holger Schulz
- Pioh, private practice for hematology and oncology, Cologne, Germany
| | | | - Konrad Frank
- Department III of Internal Medicine, University of Cologne, Cologne, Germany
| | - Reinhard Buettner
- Institute of Pathology, University Hospital Cologne and Center for Integrated Oncology Köln-Bonn, Cologne, Germany
| | - Juergen Wolf
- Lung Cancer Group Cologne, Center for Integrated Oncology, University Hospital Cologne, Koeln, Germany
| |
Collapse
|
20
|
Gardizi M, Scheffler M, Heukamp LC, Bos MCA, Albus K, Hayn B, Ko YD, Schlesinger A, Brockmann M, Serke MH, Gerigk U, Hekmat K, Stoelben E, Reiser M, Schnell R, Schmitz SH, Frank K, Buettner R, Wolf J, Zander T. Frequency and clinical characterization of NSCLC patients harboring PIK3CA mutations identified within a regional screening network. J Clin Oncol 2012. [DOI: 10.1200/jco.2012.30.15_suppl.10526] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
10526 Background: PIK3CA mutations are a rare oncogenic event of potential therapeutic relevance in NSCLC. Here we report frequency and characteristics of patients with PIK3CA mutated lung tumors. Methods: Patients with NSCLC and PIK3CA mutations were identified within our regional Network for Molecular Screening in Lung Cancer. We further analyzed the presence of BRAF, KRAS, EGFR mutations as well as ALK translocation, ERBB2 and FGFR1 amplifications in PIK3CA mutated samples. Clinical data on age, sex, TNM classification and tumor stage, histological type, grading, overall survival, smoking status, comorbidity, BMI and secondary malignancies were retrieved from clinical charts in accordance with the local ethics committee. Results: PIK3CA mutations were detected with a frequency of 3.7% (24% exon 20,76% exon 9) in 1000 patients. Histologically 32% were defined as squamous cell carcinoma, 48% as adenocarcinoma and 18% other histological subtypes or NSCLC-NOS. Exon 9 mutations were present in the acinar and lepidic subtype, whereas exon 20 mutations were seen in the papillary and solid subtype. Cooccuring genetic lesions were observed in 16% (mutations in KRAS=2, EGFR=1, BRAF=1; FGFR1 amplification=2). 14 were female, 23 male with a mean age of 69 years. 21 of these patients were further clinically annotated. 11 patients presented with stage IIIb/IV eligible for palliative treatment and 10 stage I – IIIa eligible for surgical therapy +/- adjuvant therapy. All but 1 patient were smokers with an average BMI of 26,2kg/m2 with a typical high load of comorbidity mainly of cardiovascular diseases, 8 of 21 patients showed prior malignancies in their medical history. The median overall survival within this population has not been reached yet. Conclusions: Screening for PIK3CA mutations is feasible. A high proportion (38%) of patients with PIK3CA mutated lung cancer have prior malignancies and show a high load of comorbidity. Furthermore PIK3CA mutations are not exclusive to KRAS, EGFR or BRAF mutations or FGFR1 amplifications. Successful identification of patients with oncogenic lesions in lung cancer in a screening network might allow future personalized treatment of these patients.
Collapse
Affiliation(s)
- Masyar Gardizi
- Lung Cancer Group Cologne, Center for Integrated Oncology, University Hospital Cologne, Cologne, Germany
| | - Matthias Scheffler
- Lung Cancer Group Cologne, Center for Integrated Oncology, University Hospital Cologne, Cologne, Germany
| | - Lukas Carl Heukamp
- Institute of Pathology, University Hospital Cologne and Center for Integrated Oncology Köln-Bonn, Cologne, Germany
| | - Marc Christiaan Allardt Bos
- Lung Cancer Group Cologne, Department I of Internal Medicine and Center for Integrated Oncology, University Hospital Cologne, Cologne, Germany
| | - Kerstin Albus
- Institute of Pathology, University Hospital Cologne and Center for Integrated Oncology Köln-Bonn, Cologne, Germany
| | - Birgit Hayn
- Department I of Internal Medicine and Center for Integrated Oncology Köln-Bonn, University of Cologne, Cologne, Germany
| | | | | | - Michael Brockmann
- Institute for Pathology, Hospital of the City of Cologne, Merheim, University Hospital Witten/Herdecke, Cologne, Germany
| | | | - Ulrich Gerigk
- Evangelische Kliniken Johanniter-und Waldkrankenhaus Bonn GmbH, Bonn, Germany
| | - Khosro Hekmat
- Department of Cardiothroracic Surgery, University of Cologne, Cologne, Germany
| | - Erich Stoelben
- Lung Clinic, Hospital of the City of Cologne, Cologne, Germany
| | - Marcel Reiser
- Pioh, private practice for hematology and oncology, 50226 Frechen/Cologne, Germany, Cologne, Germany
| | - Roland Schnell
- Pioh, private practice for hematology and oncology, Frechen/Cologne, Germany, Cologne, Germany
| | | | - Konrad Frank
- Department III of Internal Medicine, University of Cologne, Cologne, Germany
| | - Reinhard Buettner
- Institute of Pathology, University Hospital Cologne and Center for Integrated Oncology Köln-Bonn, Cologne, Germany
| | - Jurgen Wolf
- Lung Cancer Group Cologne, Center for Integrated Oncology, University Hospital Cologne, Cologne, Germany
| | - Thomas Zander
- Lung Cancer Group Cologne, Center for Integrated Oncology, University Hospital Cologne, Cologne, Germany
| |
Collapse
|
21
|
Bos MCA, Gardizi M, Heukamp LC, Schildhaus HU, Nogova L, Ko YD, Schlesinger A, Brockmann M, Serke MH, Gerigk U, Hekmat K, Stoelben E, Reiser M, Engel-Riedel W, Schnell R, Schmitz SH, Frank K, Buettner R, Wolf J, Zander T. Clinical characteristics and natural history of patients with squamous cell lung carcinoma with FGFR1 amplification. J Clin Oncol 2012. [DOI: 10.1200/jco.2012.30.15_suppl.1533] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
1533 Background: FGFR1 amplifications have been described as a promising oncogenic target in squamous cell lung cancer. Here we aimed at describing the clinical characteristics and natural history of FGFR1amplified squamous cell lung cancer patients. Methods: From 01/2011 to 01/2012 we screened 553 squamous cell lung cancer patients in our Network for Molecular Screening of Lung Cancer for the presence of FGFR1 amplifications by FISH analysis in accordance with the local ethics committee. FGFR1 was defined as amplified if the ratio of FGFR1 copies to centromeric copies was above 2 or if more than 50% of tumor cells showed 5 copies or if more than 15% of tumor cells demonstrated clusters of FGFR1. Clinical data were collected by extracting information from medical records, the local cancer registry and by questioning treating physicians and patients. Results: FGFR1FISH analysis could be performed in 95% of the cases and was amplified in 16%. Of the amplified cases 75 % were male and 25% female without significant enrichment for male or female. The median age of the patients at diagnosis was 67 yrs (range 46 - 82). Stage at presentation was: 16% I; 17.3% II; 26.7% IIIa, 40% IIIb/IV. 97,3% of the patients were former or active smokers with a median of 40 pack years. The median progression free survival of patients with stage IIIb/IV disease was 11 months (95% CI 8-14; n=14). The median overall survival was not yet reached after a median follow-up time of 14 months (95% CI 11 - 17; n=24). We further screened for co-existing genetic lesions such as mutations in EGFR, BRAF, KRAS, PIK3CA as well as translocations of ALK and amplifications of ERBB2. Two patients demonstrated co-occurring PIK3CA mutations and one a BRAFmutation. Conclusions: Screening for FGFR1 is feasible under routine clinical conditions. By implementation of a regional molecular screening network the ability to screen for FGFR1 amplification was successfully expanded to non-academic centers and private practices. FGFR1 amplifications in squamous cell cancer of the lung are frequent (16%) and associated with smoking history. Screening for FGFR1 might pave the way for the application of new FGFR1 directed targeted drugs in squamous cell lung cancer.
Collapse
Affiliation(s)
- Marc Christiaan Allardt Bos
- Lung Cancer Group Cologne, Department I of Internal Medicine and Center for Integrated Oncology, University Hospital Cologne, Cologne, Germany
| | - Masyar Gardizi
- Department I of Internal Medicine and Center for Integrated Oncology Köln-Bonn, Cologne, Germany
| | - Lukas Carl Heukamp
- Institute of Pathology, University Hospital Cologne and Center for Integrated Oncology Köln-Bonn, Cologne, Germany
| | | | - Lucia Nogova
- Lung Cancer Group Cologne, Center for Integrated Oncology, University Hospital Cologne, Cologne, Germany
| | | | | | - Michael Brockmann
- Institute for Pathology, Hospital of the City of Cologne, Merheim, University Hospital Witten/Herdecke, Cologne, Germany
| | | | - Ulrich Gerigk
- Evangelische Kliniken Johanniter-und Waldkrankenhaus Bonn GmbH, Bonn, Germany
| | - Khosro Hekmat
- Department of Cardiothroracic Surgery, University of Cologne, Cologne, Greenland
| | - Erich Stoelben
- Lung Clinic, Hospital of the City of Cologne, Cologne, Germany
| | - Marcel Reiser
- Pioh, private practice for hematology and oncology, 50226 Frechen/Cologne, Germany, Cologne, Germany
| | - Walburga Engel-Riedel
- Lung Clinic, Hospital of the City of Cologne, Merheim, University Hospital Witten/Herdecke, Cologne, Germany
| | - Roland Schnell
- Pioh, private practice for hematology and oncology, Frechen/Cologne, Germany, Cologne, Germany
| | | | - Konrad Frank
- Department III of Internal Medicine, University of Cologne, Cologne, Germany
| | - Reinhard Buettner
- Institute of Pathology, University Hospital Cologne and Center for Integrated Oncology Köln-Bonn, Cologne, Germany
| | - Juergen Wolf
- Lung Cancer Group Cologne, Center for Integrated Oncology, University Hospital Cologne, Koeln, Germany
| | - Thomas Zander
- Lung Cancer Group Cologne, Center for Integrated Oncology, University Hospital Cologne, Cologne, Germany
| |
Collapse
|